Background/purpose:The aim of this study is to characterize the pattern and the severity of coronary artery lesions in cardiac amyloidosis. Continue reading →

This article was originally published here J Cardiovasc Med (Hagerstown). 2020 Nov;21(11):869-873 Continue reading →

The FDA has granted a Breakthrough Therapy designation to IMGN632 as treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasms (BPDCN), ImmunoGen, Inc., announced in a press release. We are pleased FDA has granted Breakthrough Therapy designation for IMGN632, our novel CD123-targeted ADC, as it underscores the urgent need for effective and well-tolerated treatments for patients with this rare and aggressive cancer, said Mark Enyedy, president and chief executive officer, ImmunoGen, in a statement. We look forward to continuing to work with FDA to further define the development path for IMGN632 in BPDCN, in addition to pursuing our ongoing evaluation of IMGN632 in AML and other hematological malignancies. Continue reading →

opinion Matthew T. Mangino | For The Times The National Commission on COVID-19 and Criminal Justice issued its interim report looking at ways to reduce the pandemic's impact on jails and prisons as well as the courts and law enforcement. The pandemic has consumed every facet of life across the country and around the world Continue reading →

Abstract Objective To evaluate the effect of five years of supervised exercise training compared with recommendations for physical activity on mortality in older adults (70-77 years). Design Randomised controlled trial. Setting General population of older adults in Trondheim, Norway Continue reading →

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. Continue reading →